Novel biomarkers are required to discern between breast tumors that should be targeted for treatment from those that would never become clinically apparent and/or life threatening for patients. Moreover, therapeutics that specifically target breast cancer (BC) cells with tumor-initiating capacity to prevent recurrence are an unmet need. | LGR5 in breast cancer and ductal carcinoma in situ A diagnostic and prognostic biomarker and a therapeutic target